Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alamo Pharmaceuticals
FazaClo granted monthly safety monitoring by U.S. FDA
June 22nd, 2005
Alamo Pharmaceuticals announced that the U.S Food and Drug Administration (FDA) has granted FazaClo (clozapine USP) - a product for patients with treatment- resistant schizophrenia-the new option of monthly safety monitoring - a move that will bring new levels of convenience to thousands of clozapine patients and healthcare providers Like all products containing the active ingredient clozapine, treatment with FazaClo is monitored prior to filling each prescription and refill in order to limit the risk of agranulocytosis, a rare but serious side effect that affects the blood. As each FazaClo patient's blood tests show acceptable white blood cell counts, the data is...
Source: Physician Law Weekly (2005-06-22)
|
